Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Functional defects in Clostridium difficile TcdB toxin uptake identify CSPG4 receptor-binding determinants.

Gupta P, Zhang Z, Sugiman-Marangos SN, Tam J, Raman S, Julien JP, Kroh HK, Lacy DB, Murgolo N, Bekkari K, Therien AG, Hernandez LD, Melnyk RA.

J Biol Chem. 2017 Oct 20;292(42):17290-17301. doi: 10.1074/jbc.M117.806687. Epub 2017 Aug 23.

2.

Epitopes and Mechanism of Action of the Clostridium difficile Toxin A-Neutralizing Antibody Actoxumab.

Hernandez LD, Kroh HK, Hsieh E, Yang X, Beaumont M, Sheth PR, DiNunzio E, Rutherford SA, Ohi MD, Ermakov G, Xiao L, Secore S, Karczewski J, Racine F, Mayhood T, Fischer P, Sher X, Gupta P, Lacy DB, Therien AG.

J Mol Biol. 2017 Apr 7;429(7):1030-1044. doi: 10.1016/j.jmb.2017.02.010. Epub 2017 Feb 21.

PMID:
28232034
3.

Disease Progression and Resolution in Rodent Models of Clostridium difficile Infection and Impact of Antitoxin Antibodies and Vancomycin.

Warn P, Thommes P, Sattar A, Corbett D, Flattery A, Zhang Z, Black T, Hernandez LD, Therien AG.

Antimicrob Agents Chemother. 2016 Oct 21;60(11):6471-6482. doi: 10.1128/AAC.00974-16. Print 2016 Nov.

4.

Correction for Zhang et al., Toxin-mediated paracellular transport of antitoxin antibodies facilitates protection against Clostridium difficile infection.

Zhang Z, Chen X, Hernandez LD, Lipari P, Flattery A, Chen SC, Kramer S, Polishook JD, Racine F, Cape H, Kelly CP, Therien AG.

Infect Immun. 2015 Dec;83(12):4899. doi: 10.1128/IAI.01214-15. No abstract available.

5.

Small molecule inhibitors of Clostridium difficile toxin B-induced cellular damage.

Tam J, Beilhartz GL, Auger A, Gupta P, Therien AG, Melnyk RA.

Chem Biol. 2015 Feb 19;22(2):175-85. doi: 10.1016/j.chembiol.2014.12.010. Epub 2015 Jan 22.

6.

Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab.

Yang Z, Ramsey J, Hamza T, Zhang Y, Li S, Yfantis HG, Lee D, Hernandez LD, Seghezzi W, Furneisen JM, Davis NM, Therien AG, Feng H.

Infect Immun. 2015 Feb;83(2):822-31. doi: 10.1128/IAI.02897-14. Epub 2014 Dec 8.

7.

Broad coverage of genetically diverse strains of Clostridium difficile by actoxumab and bezlotoxumab predicted by in vitro neutralization and epitope modeling.

Hernandez LD, Racine F, Xiao L, DiNunzio E, Hairston N, Sheth PR, Murgolo NJ, Therien AG.

Antimicrob Agents Chemother. 2015 Feb;59(2):1052-60. doi: 10.1128/AAC.04433-14. Epub 2014 Dec 1.

8.

Toxin-mediated paracellular transport of antitoxin antibodies facilitates protection against Clostridium difficile infection.

Zhang Z, Chen X, Hernandez LD, Lipari P, Flattery A, Chen SC, Kramer S, Polishook JD, Racine F, Cape H, Kelly CP, Therien AG.

Infect Immun. 2015 Jan;83(1):405-16. doi: 10.1128/IAI.02550-14. Epub 2014 Nov 10. Erratum in: Infect Immun. 2015 Dec;83(12):4899.

9.

Mechanism of action and epitopes of Clostridium difficile toxin B-neutralizing antibody bezlotoxumab revealed by X-ray crystallography.

Orth P, Xiao L, Hernandez LD, Reichert P, Sheth PR, Beaumont M, Yang X, Murgolo N, Ermakov G, DiNunzio E, Racine F, Karczewski J, Secore S, Ingram RN, Mayhood T, Strickland C, Therien AG.

J Biol Chem. 2014 Jun 27;289(26):18008-21. doi: 10.1074/jbc.M114.560748. Epub 2014 May 12.

10.

Gene expression profiling following NRF2 and KEAP1 siRNA knockdown in human lung fibroblasts identifies CCL11/Eotaxin-1 as a novel NRF2 regulated gene.

Fourtounis J, Wang IM, Mathieu MC, Claveau D, Loo T, Jackson AL, Peters MA, Therien AG, Boie Y, Crackower MA.

Respir Res. 2012 Oct 12;13:92. doi: 10.1186/1465-9921-13-92.

11.

Broadening the spectrum of β-lactam antibiotics through inhibition of signal peptidase type I.

Therien AG, Huber JL, Wilson KE, Beaulieu P, Caron A, Claveau D, Deschamps K, Donald RG, Galgoci AM, Gallant M, Gu X, Kevin NJ, Lafleur J, Leavitt PS, Lebeau-Jacob C, Lee SS, Lin MM, Michels AA, Ogawa AM, Painter RE, Parish CA, Park YW, Benton-Perdomo L, Petcu M, Phillips JW, Powles MA, Skorey KI, Tam J, Tan CM, Young K, Wong S, Waddell ST, Miesel L.

Antimicrob Agents Chemother. 2012 Sep;56(9):4662-70. doi: 10.1128/AAC.00726-12. Epub 2012 Jun 18.

12.

Restoring methicillin-resistant Staphylococcus aureus susceptibility to β-lactam antibiotics.

Tan CM, Therien AG, Lu J, Lee SH, Caron A, Gill CJ, Lebeau-Jacob C, Benton-Perdomo L, Monteiro JM, Pereira PM, Elsen NL, Wu J, Deschamps K, Petcu M, Wong S, Daigneault E, Kramer S, Liang L, Maxwell E, Claveau D, Vaillancourt J, Skorey K, Tam J, Wang H, Meredith TC, Sillaots S, Wang-Jarantow L, Ramtohul Y, Langlois E, Landry F, Reid JC, Parthasarathy G, Sharma S, Baryshnikova A, Lumb KJ, Pinho MG, Soisson SM, Roemer T.

Sci Transl Med. 2012 Mar 21;4(126):126ra35. doi: 10.1126/scitranslmed.3003592.

13.

Discovery of novel P2Y14 agonist and antagonist using conventional and nonconventional methods.

Hamel M, Henault M, Hyjazie H, Morin N, Bayly C, Skorey K, Therien AG, Mancini J, Brideau C, Kargman S.

J Biomol Screen. 2011 Oct;16(9):1098-105. doi: 10.1177/1087057111415525. Epub 2011 Aug 5.

PMID:
21821827
14.

Naphthalene/quinoline amides and sulfonylureas as potent and selective antagonists of the EP4 receptor.

Burch JD, Farand J, Colucci J, Sturino C, Ducharme Y, Friesen RW, Lévesque JF, Gagné S, Wrona M, Therien AG, Mathieu MC, Denis D, Vigneault E, Xu D, Clark P, Rowland S, Han Y.

Bioorg Med Chem Lett. 2011 Feb 1;21(3):1041-6. doi: 10.1016/j.bmcl.2010.12.014. Epub 2010 Dec 8.

PMID:
21215624
15.

The identification of substituted benzothiophene derivatives as PGE(2) subtype 4 receptor antagonists: From acid to non-acid.

Li L, Mathieu MC, Denis D, Therien AG, Wang Z.

Bioorg Med Chem Lett. 2011 Jan 15;21(2):734-7. doi: 10.1016/j.bmcl.2010.11.118. Epub 2010 Dec 3.

PMID:
21208803
16.

Discovery of 4-[1-[([1-[4-(trifluoromethyl)benzyl]-1H-indol-7-yl]carbonyl)amino]cyclopropyl]benzoic acid (MF-766), a highly potent and selective EP4 antagonist for treating inflammatory pain.

Colucci J, Boyd M, Berthelette C, Chiasson JF, Wang Z, Ducharme Y, Friesen R, Wrona M, Levesque JF, Denis D, Mathieu MC, Stocco R, Therien AG, Clarke P, Rowland S, Xu D, Han Y.

Bioorg Med Chem Lett. 2010 Jun 15;20(12):3760-3. doi: 10.1016/j.bmcl.2010.04.065. Epub 2010 Apr 18.

PMID:
20471829
17.

Mutual antagonistic relationship between prostaglandin E(2) and IFN-gamma: Implications for rheumatoid arthritis.

Mathieu MC, Lord-Dufour S, Bernier V, Boie Y, Burch JD, Clark P, Denis D, Han Y, Mortimer JR, Therien AG.

Eur J Immunol. 2008 Jul;38(7):1900-12. doi: 10.1002/eji.200838170.

18.

Structure-activity relationships and pharmacokinetic parameters of quinoline acylsulfonamides as potent and selective antagonists of the EP(4) receptor.

Burch JD, Belley M, Fortin R, Deschênes D, Girard M, Colucci J, Farand J, Therien AG, Mathieu MC, Denis D, Vigneault E, Lévesque JF, Gagné S, Wrona M, Xu D, Clark P, Rowland S, Han Y.

Bioorg Med Chem Lett. 2008 Mar 15;18(6):2048-54. doi: 10.1016/j.bmcl.2008.01.103. Epub 2008 Jan 31.

PMID:
18291643
19.

MF498 [N-{[4-(5,9-Diethoxy-6-oxo-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl)-3-methylbenzyl]sulfonyl}-2-(2-methoxyphenyl)acetamide], a selective E prostanoid receptor 4 antagonist, relieves joint inflammation and pain in rodent models of rheumatoid and osteoarthritis.

Clark P, Rowland SE, Denis D, Mathieu MC, Stocco R, Poirier H, Burch J, Han Y, Audoly L, Therien AG, Xu D.

J Pharmacol Exp Ther. 2008 May;325(2):425-34. doi: 10.1124/jpet.107.134510. Epub 2008 Feb 20.

PMID:
18287210
20.

Adenovirus IL-13-induced airway disease in mice: a corticosteroid-resistant model of severe asthma.

Therien AG, Bernier V, Weicker S, Tawa P, Falgueyret JP, Mathieu MC, Honsberger J, Pomerleau V, Robichaud A, Stocco R, Dufresne L, Houshyar H, Lafleur J, Ramachandran C, O'Neill GP, Slipetz D, Tan CM.

Am J Respir Cell Mol Biol. 2008 Jul;39(1):26-35. doi: 10.1165/rcmb.2007-0240OC. Epub 2008 Feb 7.

PMID:
18258919
21.

Expression and function of NPSR1/GPRA in the lung before and after induction of asthma-like disease.

Allen IC, Pace AJ, Jania LA, Ledford JG, Latour AM, Snouwaert JN, Bernier V, Stocco R, Therien AG, Koller BH.

Am J Physiol Lung Cell Mol Physiol. 2006 Nov;291(5):L1005-17. Epub 2006 Jul 7.

22.

Structure-function relationships in the neuropeptide S receptor: molecular consequences of the asthma-associated mutation N107I.

Bernier V, Stocco R, Bogusky MJ, Joyce JG, Parachoniak C, Grenier K, Arget M, Mathieu MC, O'Neill GP, Slipetz D, Crackower MA, Tan CM, Therien AG.

J Biol Chem. 2006 Aug 25;281(34):24704-12. Epub 2006 Jun 20.

23.

The C3a receptor antagonist SB 290157 has agonist activity.

Mathieu MC, Sawyer N, Greig GM, Hamel M, Kargman S, Ducharme Y, Lau CK, Friesen RW, O'Neill GP, Gervais FG, Therien AG.

Immunol Lett. 2005 Sep 15;100(2):139-45. Epub 2005 Mar 25.

PMID:
16154494
24.

Agonist activity of the small molecule C3aR ligand SB 290157.

Therien AG.

J Immunol. 2005 Jun 15;174(12):7479; author reply 7479-80. No abstract available.

25.

Non-native interhelical hydrogen bonds in the cystic fibrosis transmembrane conductance regulator domain modulated by polar mutations.

Choi MY, Cardarelli L, Therien AG, Deber CM.

Biochemistry. 2004 Jun 29;43(25):8077-83.

PMID:
15209503
26.
27.

Modulation of Na,K-ATPase by the gamma subunit: studies with transfected cells and transmembrane mimetic peptides.

Zouzoulas A, Therien AG, Scanzano R, Deber CM, Blostein R.

J Biol Chem. 2003 Oct 17;278(42):40437-41. Epub 2003 Aug 7.

28.

Polar mutations in membrane proteins as a biophysical basis for disease.

Partridge AW, Therien AG, Deber CM.

Biopolymers. 2002;66(5):350-8.

PMID:
12539263
30.
31.

Putting the beta-breaks on membrane protein misfolding.

Deber CM, Therien AG.

Nat Struct Biol. 2002 May;9(5):318-9. No abstract available.

PMID:
11976722
32.

Molecular and functional studies of the gamma subunit of the sodium pump.

Therien AG, Pu HX, Karlish SJ, Blostein R.

J Bioenerg Biomembr. 2001 Oct;33(5):407-14. Review.

PMID:
11762916
33.
34.

Interhelical hydrogen bonds in the CFTR membrane domain.

Therien AG, Grant FE, Deber CM.

Nat Struct Biol. 2001 Jul;8(7):597-601.

PMID:
11427889
35.

Mechanisms of sodium pump regulation.

Therien AG, Blostein R.

Am J Physiol Cell Physiol. 2000 Sep;279(3):C541-66. Review.

36.

K(+)/Na(+) antagonism at cytoplasmic sites of Na(+)-K(+)-ATPase: a tissue-specific mechanism of sodium pump regulation.

Therien AG, Blostein R.

Am J Physiol. 1999 Nov;277(5):C891-8. doi: 10.1152/ajpcell.1999.277.5.C891.

PMID:
10564082
37.

Expression and functional role of the gamma subunit of the Na, K-ATPase in mammalian cells.

Therien AG, Karlish SJ, Blostein R.

J Biol Chem. 1999 Apr 30;274(18):12252-6.

38.

Tissue-specific distribution and modulatory role of the gamma subunit of the Na,K-ATPase.

Therien AG, Goldshleger R, Karlish SJ, Blostein R.

J Biol Chem. 1997 Dec 19;272(51):32628-34.

39.

Tissue-specific versus isoform-specific differences in cation activation kinetics of the Na,K-ATPase.

Therien AG, Nestor NB, Ball WJ, Blostein R.

J Biol Chem. 1996 Mar 22;271(12):7104-12.

Supplemental Content

Loading ...
Support Center